AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Tat-expressing Sendai viral vector-booster does not increase protection.

Vaccine Weekly

| September 03, 2003 | COPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2003 SEP 3 - (NewsRx.com & NewsRx.net) -- No significant enhancement of protection by Tat-expressing Sendai viral vector-booster occurred in a macaque AIDS model.

According to a study from Japan, "We previously developed a DNA-prime/Gag-expressing Sendai virus (SeV) vector-boost vaccine system, and showed its excellent protective efficacy against a pathogenic SHIV infection in macaques. Alternative antigens may be used instead or together with Gag for the booster."

"We examined the potential of Tat as the booster antigen in our DNA-prime/SeV-boost system," reported Tetsuro Matano and colleagues at the University of Tokyo. "However, boosting by Tat-expressing SeV induced no significant enhancement of protection against SHIV infections."

Related articles from newspapers, magazines, journals, and more
SYNTRO VIRAL VECTOR VACCINE APPROVED FOR FINAL TESTING
Press release article from: PR Newswire April 4, 1994 700+ words
...field trials with the Company's first viral vector vaccine for poultry. The official USDA...the first commercial application of viral vector technology in any species. Evaluating...for the vaccine within six months. Viral vector technology is receiving increased attention...
Viral vector-mediated endostatin transfer halts pancreatic cancer growth.
Newspaper article from: Gastroenterology Week December 27, 2004 700+ words
2004 DEC 27 - (NewsRx.com & NewsRx.net) -- Viral vector-mediated endostatin transfer halts pancreatic cancer growth...published their study in Cancer Research (Adeno-associated viral vector-mediated expression of endostatin inhibits tumor growth...
Puresyn Receives Second Phase II SBIR Grant; US Government Funds $750,000 for...
Press release article from: PR Newswire June 21, 2002 700+ words
...grant Puresyn has received related to production-scale viral vector purification. Puresyn will employ its proprietary PolyFlo...for process-scale manufacturing of plasmid-based and viral vector- based gene therapies, and is introducing a new line of...
Publication No. WO/2009/134681 Published on Nov. 5, Assigned to Trustees of the...
News wire article from: US Fed News Service, Including US State News November 9, 2009 700+ words
...subject's eye a dose of about 109 genome copies of an AAV7 viral vector and a minigene comprising sequences encoding the gene product...RPE65 protein in RPE cells and is delivered via the AAV7 viral vector." The invention carries International Patent Publication...
Patent No. 7,598,225 Issued on Oct. 6, Assigned to U.S. Department of Health...
News wire article from: US Fed News Service, Including US State News October 12, 2009 700+ words
...Acton, Mass., have developed a method of using recombinant viral vector. The inventors were issued U.S. Patent No. 7,598...Office: "We have discovered that by using a recombinant viral vector, preferably a pox virus vector having at least one insertion...
Vaporized viral vector shows promise in anti-cancer gene therapy.
Newspaper article from: NewsRx Health June 28, 2009 700+ words
A new lung cancer therapy employing a vaporized viral vector to deliver a cancer-inhibiting molecule directly to lung tissue shows early promise in mouse trials, according to researchers...
NEW ARTIFICIAL VIRAL VECTOR FROM JAPAN OFFERS SAFER GENE THERAPY.
News wire article from: AsiaPulse News November 27, 2007 700+ words
TOKYO, Nov 27 Asia Pulse - A research team at Hokkaido University has developed an improved artificial viral vector for safely delivering genes into cells for gene therapy. Gene therapy now relies mainly on the adenovirus and other real viruses...
Serial doses of aerosolized viral vector do well in nonhuman primates.
Newspaper article from: Health & Medicine Week February 2, 2004 700+ words
2004 FEB 2 - (NewsRx.com & NewsRx.net) -- Serial doses of aerosolized viral vector do well in nonhuman primates. According to recent research published in the journal Molecular Therapy, "bronchoscopic microspraying...
For more facts and information, see all results

Source: HighBeam Research, Tat-expressing Sendai viral vector-booster does not increase...

©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA